1. Репозитарій НУОЗ України імені П. Л. Шупика
  2. Український державний інститут репродуктології
  3. Кафедра медичної та лабораторної генетики
Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал: http://lib.inmeds.com.ua:8080/jspui/handle/lib/4722
Повний запис метаданих
Поле DCЗначенняМова
dc.contributor.authorБенціонова, К.І.-
dc.contributor.authorРоссоха, З.І.-
dc.contributor.authorЄвсеєнкова, О.Г.-
dc.contributor.authorГоровенко, Н.Г.-
dc.date.accessioned2023-11-17T11:46:01Z-
dc.date.available2023-11-17T11:46:01Z-
dc.date.issued2023-
dc.identifier.citationhttps://doi.org/10.26641/2307-0404.2023.1.275870uk_UK
dc.identifier.issnISSN (online) 2786-4804-
dc.identifier.urihttp://lib.inmeds.com.ua:8080/jspui/handle/lib/4722-
dc.descriptionThromboembolic diseases are of great clinical concern because of their high prevalence and consequences, which are often fatal. Despite significant progress in the prevention and treatment of thrombotic events, patients remain at risk of life-threatening bleeding episodes and other side effects arising from anticoagulant therapy, so the issue of personalizing prescriptions taking into account the genetic characteristics of patients has become urgent. The purpose of the study is to substantiate the need for patient genotype analysis in order to increase the effectiveness and safety of individual pharmacotherapy. The article has a conceptual nature, therefore the following research methods were chosen: systematization and generalization; analysis and specification; abstract and logical. For the search, we used Pub Med, Pub Med Central, Google Scholar, db SNP. Elsevier; Springer from September 2000 to November 2022. The review included studies written in English and Ukrainian. There were analyzed literature data on two main subclasses of oral antithrombotic agents, including oral anticoagulants and anti plate let agents, namely war far in, apixaban, rivaroxaban, and clopidogrel. Prognosticate significant for evaluating the effectiveness and safety of anticoagulant use, as well as the most studied in this aspect, are CYP2C9 (rs1799853, rs1057910), CYP2C19 (rs4244285, rs49S6S93, rs!224S560), VKORC1 (rs9923231, rs7294, rs9934438), MDR1 (rs4148738, rs2032582, rs1045642), FGB (rs1800787), PAI-1 (rs1799889) genes. The results ofCYP2B6, CYP3A4/5 (rs776746), CYP4F2 (rs2108622) genes analysis indicate a certain influence on the anticoagulants metabolism and require further detailed study. Factors such as age, race, sex, smoking, diet, and other medications are known to influence the effectiveness of antithrombotic therapy, but the most influential factor is genetics, which accounts a significant percentage of inter individual variability. Future research should focus on the study of blown and novel genetic variants that influence drug metabolism, as well as the molecular mechanisms that contribute to changes in plasma anticoagulant levels. The article provides a brief overview of action mechanisms, pharmacogenetics, and interactions between drugs and the genes responsible for their metabolism. The results indicate the need for studies of gene variants considered in this review before starting anticoagulant therapy, and attention should also be paid to the possibility of inhibitors and inductors influence on components of the metabolic pathway of anticoagulants and gene expression products that participate in their metabolism. The totality of these measures will ensure an increase in the efficiency and safety of individual pharmacotherapy and allow optimizing the choice and dosage of anticoagulants. © 2023 Dnipro State Medical University. All rights reserved.uk_UK
dc.description.abstractThromboembolic diseases are of great clinical concern because of their high prevalence and consequences, which are often fatal. Despite significant progress in the prevention and treatment of thrombotic events, patients remain at risk of life-threatening bleeding episodes and other side effects arising from anticoagulant therapy, so the issue of personalizing prescriptions taking into account the genetic characteristics of patients has become urgent. The purpose of the study is to substantiate the need for patient genotype analysis in order to increase the effectiveness and safety of individual pharmacotherapy.uk_UK
dc.language.isootheruk_UK
dc.publisherМЕДИЧНІ ПЕРСПЕКТИВИuk_UK
dc.relation.ispartofseriesТ.28, №1;С.55-68-
dc.subjectThromboembolic diseasesuk_UK
dc.subjectanticoagulant therapyuk_UK
dc.subjectindividual pharmacotherapyuk_UK
dc.subjectgenotype analysisuk_UK
dc.subjectrivaroxabanuk_UK
dc.subjectapixabanuk_UK
dc.subjectinhibitorsuk_UK
dc.subjectwarfarinuk_UK
dc.titleФармакогенетичне обґрунтування персоналізованого призначення пероральних антикоагулянтних препаратів у клінічній практиціuk_UK
dc.title.alternativePharmacogenetic substantiation of personalized prescription of oral anticoagulants in clinical practiceuk_UK
dc.typeArticleuk_UK
Розташовується у зібраннях:Кафедра медичної та лабораторної генетики

Файли цього матеріалу:
Файл Опис РозмірФормат 
Фармакогенетичне обґрунтування персоналізованого призначення пероральних антикоагулянтних препаратів у клінічній практиці.docxосновна стаття279.94 kBMicrosoft Word XMLПереглянути/Відкрити
Показати базовий опис матеріалу Перегляд статистики


Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.